Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and ‘salvage’ in patients with high risk locally advanced rectal cancers – tolerance and early outcomes

Ramjas Prajapati, Vikas Ostwal, Sujay Srinivas, Reena Engineer, Prabhat Bhargava, Avanish Saklani, Ashwin D’Souza, Suman Kumar, Zoya Peelay, P. Manali, Anant Ramaswamy

Open source

DOI
10.4103/jcrt.jcrt_225_22
Published
2023-04-07
Container
Journal of Cancer Research and Therapeutics
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.4103/jcrt.jcrt_225_22,
  title = {Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and ‘salvage’ in patients with high risk locally advanced rectal cancers – tolerance and early outcomes},
  author = {Ramjas Prajapati and Vikas Ostwal and Sujay Srinivas and Reena Engineer and Prabhat Bhargava and Avanish Saklani and Ashwin D’Souza and Suman Kumar and Zoya Peelay and P. Manali and Anant Ramaswamy},
  year = {2023},
  journal = {Journal of Cancer Research and Therapeutics},
  doi = {10.4103/jcrt.jcrt_225_22},
  url = {https://doi.org/10.4103/jcrt.jcrt_225_22}
}

RIS

TY  - JOUR
TI  - Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and ‘salvage’ in patients with high risk locally advanced rectal cancers – tolerance and early outcomes
AU  - Ramjas Prajapati
AU  - Vikas Ostwal
AU  - Sujay Srinivas
AU  - Reena Engineer
AU  - Prabhat Bhargava
AU  - Avanish Saklani
AU  - Ashwin D’Souza
AU  - Suman Kumar
AU  - Zoya Peelay
AU  - P. Manali
AU  - Anant Ramaswamy
PY  - 2023
JO  - Journal of Cancer Research and Therapeutics
DO  - 10.4103/jcrt.jcrt_225_22
UR  - https://doi.org/10.4103/jcrt.jcrt_225_22
ER  - 

APA

Prajapati, R., Ostwal, V., Srinivas, S., Engineer, R., Bhargava, P., Saklani, A., D’Souza, A., Kumar, S., Peelay, Z., Manali, P., & Ramaswamy, A. (2023). Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and ‘salvage’ in patients with high risk locally advanced rectal cancers – tolerance and early outcomes. Journal of Cancer Research and Therapeutics. https://doi.org/10.4103/jcrt.jcrt_225_22

Source records